Shots:
- Eli Lilly reported positive topline results from the P-III (ACHIEVE-4) study of Foundayo (orforglipron) vs insulin glargine in ~2,700 pts with type 2 diabetes, and obesity or overweight with elevated CV risk, meeting the 1EP of non-inferiority in MACE-4 events
- Foundayo demonstrated a 16% lower risk of MACE-4 and 23% lower risk of MACE-3, with a 57% reduction in all-cause mortality (HR=0.43), alongside superior reductions in A1C (-1.6% vs -1.0%) and body weight (-8.8% vs +1.7%) at 52wks.
- The safety profile was consistent with the GLP-1 class, with no hepatic safety signal observed; Lilly plans to submit the NDA to the US FDA by the end of Q2 2026
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Reports P-III (BRUIN CLL-322) Trial Data on Jaypirca Combination for CLL/SLL
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
